Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Rafael Holdings, Inc. holds interests in clinical and early stage pharmaceutical companies, and commercial real estate assets in the United States and Israel. The company operates in two segments, Pharmaceuticals and Real Estate. It engages in the leasing of a commercial office building, as well as an associated 800-car public garage; and development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. The company's lead drug candidate is CPI-613 (devimistat), which is being evaluated in various clinical studies, including two Phase III registrational clinical trials for the treatment of metastatic pancreatic cancer and r/r acute myeloid leukemia. Rafael Holdings, Inc. is headquartered in Newark, New Jersey.

Rafael Holdings, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

TAMPA, FLA.--(BUSINESS WIRE)--BLOOMIN' BRANDS, INC. (NASDAQ: BLMN) ANNOUNCED THE APPOINTMENT OF RAFAEL SANCHEZ AS SENIOR VICE PRESIDENT & CHIEF INFORMATION OFFICER. SANCHEZ JOINS THE COMPANY FROM DAVIDSON HOSPITALITY GROUP WHERE HE SERVED AS SENIOR VICE PRESIDENT OF INFORMATION TECHNOLOGY. HIS APPOINTMENT IS EFFECTIVE JUNE 30, 2025. RAFAEL HAS A STRONG HISTORY IN OUT-OF-HOME ENTERTAINMENT AND RESTAURANTS, SAID MIKE SPANOS, CEO OF BLOOMIN' BRANDS, INC. HE IS A STRONG LEADER THAT FOCUSES O.

RAFAEL SANCHEZ JOINS BLOOMIN' BRANDS AS CHIEF INFORMATION OFFICER

NEWARK, N.J., JUNE 11, 2025 (GLOBE NEWSWIRE) -- RAFAEL HOLDINGS, INC.(NYSE: RFL; NYSE AMERICAN: RFL-WT), TODAY REPORTED ITS FINANCIAL RESULTS FOR THE THIRD QUARTER AND FIRST NINE MONTHS OF FISCAL YEAR 2025 ENDED APRIL 30, 2025.

RAFAEL HOLDINGS REPORTS THIRD QUARTER FISCAL 2025 FINANCIAL RESULTS

NEWARK, N.J., JUNE 04, 2025 (GLOBE NEWSWIRE) -- RAFAEL HOLDINGS, INC. (NYSE: RFL; NYSE AMERICAN: RFL-WT) ANNOUNCED TODAY THE FINAL RESULTS AND CLOSING OF ITS $25.0 MILLION RIGHTS OFFERING (THE RIGHTS OFFERING). THE SUBSCRIPTION PERIOD OF THE RIGHTS OFFERING EXPIRED AT 5:00 P.M. EASTERN TIME, ON MAY 29, 2025. THE RIGHTS OFFERING RESULTED IN SUBSCRIPTIONS FOR 3,130,480 SHARES OF CLASS B COMMON STOCK AT AN EXERCISE PRICE OF $1.28 PER SHARE FOR AGGREGATE GROSS PROCEEDS OF $4,007,014.40.THE SUBSCRIPTIONS DO NOT REFLECT SUBSCRIPTION RIGHTS HELD BY HOWARD JONAS, CHIEF EXECUTIVE OFFICER, PRESIDENT AND EXECUTIVE CHAIRMAN OF THE COMPANY AND CHAIRMAN OF THE BOARD OF DIRECTORS OF THE COMPANY, AND HIS AFFILIATES WHO HELD, PRIOR TO THE RIGHTS OFFERING, APPROXIMATELY 32% OF THE OUTSTANDING COMMON STOCK OF THE COMPANY. DUE TO MR. JONAS' PREVIOUSLY DISCLOSED COMMITMENT TO BACKSTOP THE RIGHTS OFFERING THROUGH A PRIVATE PLACEMENT OF SHARES IN THE EVENT THAT THE RIGHTS OFFERING WAS NOT FULLY SUBSCRIBED (THE BACKSTOP PRIVATE PLACEMENT), THOSE HOLDERS DID NOT EXERCISE THEIR SUBSCRIPTION RIGHTS. MR. JONAS AND CERTAIN RELATED PARTIES ARE PURCHASING THE UNSUBSCRIBED SHARES FOR AN AGGREGATE AMOUNT OF $20,992,985.60.

RAFAEL HOLDINGS, INC. ANNOUNCES FINAL RESULTS AND CLOSING OF RIGHTS OFFERING

NEWARK, N.J., MAY 20, 2025 (GLOBE NEWSWIRE) -- RAFAEL HOLDINGS, INC. (NYSE: RFL; NYSE AMERICAN: RFL-WT) TODAY PROVIDED AN UPDATE TO THE SUBSCRIPTION RIGHTS RELATED TO ITS PUBLIC WARRANTS IN CONNECTION WITH ITS PREVIOUSLY ANNOUNCED RIGHTS OFFERING.

RAFAEL HOLDINGS, INC. PROVIDES UPDATE TO THE DESCRIPTION OF SUBSCRIPTION RIGHTS RELATED TO ITS PUBLIC WARRANTS IN CONNECTION WITH ITS PREVIOUSLY ANNOUNCED $25 MILLION RIGHTS OFFERING TO SUPPORT ITS COMMITMENT TO THE DEVELOPMENT AND POTENTIAL LAUNCH OF TRAPPSOL CYCLO

DALLAS , MAY 19, 2025 /PRNEWSWIRE/ -- TEXAS INSTRUMENTS INCORPORATED (TI) (NASDAQ: TXN) SENIOR VICE PRESIDENT AND CHIEF FINANCIAL OFFICERRAFAEL LIZARDI WILL SPEAK AT THE BANK OF AMERICA 2025 GLOBAL TECHNOLOGY CONFERENCE IN SAN FRANCISCO ON WEDNESDAY, JUNE 4, AT 11:20 A.M. PACIFIC TIME.

TI CHIEF FINANCIAL OFFICER RAFAEL LIZARDI TO SPEAK AT BANK OF AMERICA INVESTOR CONFERENCE

NEWARK, N.J., MAY 05, 2025 (GLOBE NEWSWIRE) -- RAFAEL HOLDINGS, INC. (NYSE: RFL; NYSE AMERICAN: RFL-WT) TODAY ANNOUNCED REVISED SUBSCRIPTION RIGHTS IN CONNECTION WITH ITS PREVIOUSLY ANNOUNCED RIGHTS OFFERING.

RAFAEL HOLDINGS, INC. ANNOUNCES REVISED SUBSCRIPTION RIGHTS IN CONNECTION WITH ITS PREVIOUSLY ANNOUNCED $25 MILLION RIGHTS OFFERING TO SUPPORT ITS COMMITMENT TO THE DEVELOPMENT AND POTENTIAL LAUNCH OF TRAPPSOLCYCLO

NEWARK, N.J., APRIL 29, 2025 (GLOBE NEWSWIRE) -- RAFAEL HOLDINGS, INC. (NYSE: RFL; NYSE AMERICAN: RFL-WT) TODAY ANNOUNCED A RIGHTS OFFERING, INCLUDING KEY DATES AND TERMS. THE PLANNED OFFERING IS DESIGNED TO PROVIDE EXISTING STOCKHOLDERS AND HOLDERS OF OUR PUBLIC WARRANTS (HOLDERS) THE OPPORTUNITY TO PURCHASE ADDITIONAL SHARES OF RAFAEL HOLDINGS' CLASS B COMMON STOCK, PAR VALUE $0.01 PER SHARE (CLASS B COMMON STOCK), SUBJECT TO THE TERMS OUTLINED BELOW FOR AN AGGREGATE OFFERING OF $25 MILLION. THE FUNDS PROVIDE THE COMPANY ADDITIONAL CAPITAL FOR THE POTENTIAL LAUNCH OF TRAPPSOLCYCLO IN THE EVENT OF A POSITIVE INTERIM RESULT FROM THE 48-WEEK INTERIM ANALYSIS OF THE TRANSPORTNPC PHASE 3 CLINICAL TRIAL IN NIEMANN-PICK DISEASE TYPEC1 (NPC1).

RAFAEL HOLDINGS, INC. ANNOUNCES PROPOSED TERMS OF A $25 MILLION RIGHTS OFFERING TO SUPPORT ITS COMMITMENT TO THE DEVELOPMENT AND POTENTIAL LAUNCH OF TRAPPSOLCYCLO

CYCLO THERAPEUTICS' TRANSPORTNPC PHASE 3 CLINICAL TRIAL FOR TRAPPSOL  CYCLO FOR THE TREATMENT OF NIEMANN-PICK DISEASE TYPE C1, A RARE AND FATAL GENETIC DISEASE, IS FULLY ENROLLED AND RESULTS FROM THE 48-WEEK INTERIM ANALYSIS ARE EXPECTED IN THE MIDDLE OF 2025

RAFAEL HOLDINGS STRENGTHENS ITS FOCUS ON THE DEVELOPMENT OF TRAPPSOL CYCLO AND ANNOUNCES CHIEF EXECUTIVE OFFICER BILL CONKLING WILL BE STEPPING DOWN FROM HIS ROLE

CYCLO THERAPEUTICS' TRANSPORTNPC PHASE 3 CLINICAL TRIAL FOR TRAPPSOL CYCLO FOR THE TREATMENT OF NIEMANN-PICK DISEASE TYPE C1, A RARE AND FATAL GENETIC DISEASE, IS FULLY ENROLLED AND RESULTS FROM THE 48-WEEK INTERIM ANALYSIS ARE EXPECTED IN THE MIDDLE OF 2025 CYCLO THERAPEUTICS' TRANSPORTNPC PHASE 3 CLINICAL TRIAL FOR TRAPPSOL CYCLO FOR THE TREATMENT OF NIEMANN-PICK DISEASE TYPE C1, A RARE AND FATAL GENETIC DISEASE, IS FULLY ENROLLED AND RESULTS FROM THE 48-WEEK INTERIM ANALYSIS ARE EXPECTED IN THE MIDDLE OF 2025

RAFAEL HOLDINGS COMPLETES MERGER WITH CYCLO THERAPEUTICS FOLLOWING SHAREHOLDER APPROVALS

THE PLANNED MERGER WITH CYCLO THERAPEUTICS IS ANTICIPATED TO CLOSE IN Q3 PENDING SHAREHOLDER APPROVALS POST-MERGER THE COMPANY INTENDS TO FOCUS ITS EFFORTS ON CYCLO'S LEAD CLINICAL PROGRAM TRAPPSOL  CYCLO NEWARK, N.J., MARCH 13, 2025 (GLOBE NEWSWIRE) -- RAFAEL HOLDINGS, INC. (NYSE: RFL), TODAY REPORTED ITS FINANCIAL RESULTS FOR THE SECOND QUARTER AND FIRST SIX MONTHS OF FISCAL YEAR 2025 ENDED JANUARY 31, 2025.

Rafael Holdings, Inc.

RFL

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Rafael Holdings, Inc.

RFL.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

RFL